Handelsbanken Fonder AB Invests $1.42 Million in Adaptive Biotechnologies Corporation $ADPT

Handelsbanken Fonder AB bought a new stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 66,000 shares of the company’s stock, valued at approximately $1,416,000.

Other hedge funds have also bought and sold shares of the company. Caitong International Asset Management Co. Ltd acquired a new position in Adaptive Biotechnologies during the fourth quarter worth approximately $28,000. EverSource Wealth Advisors LLC lifted its position in shares of Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after buying an additional 1,565 shares during the last quarter. Assetmark Inc. lifted its position in shares of Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock valued at $49,000 after buying an additional 2,708 shares during the last quarter. T. Rowe Price Investment Management Inc. bought a new position in shares of Adaptive Biotechnologies during the 4th quarter worth approximately $51,000. Finally, Strive Financial Group LLC acquired a new position in shares of Adaptive Biotechnologies during the 4th quarter worth approximately $52,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Adaptive Biotechnologies Stock Performance

ADPT opened at $24.56 on Wednesday. The business has a fifty day simple moving average of $21.58 and a 200 day simple moving average of $17.19. The company has a market capitalization of $3.92 billion, a PE ratio of -59.90 and a beta of 2.08. Adaptive Biotechnologies Corporation has a 1 year low of $12.00 and a 1 year high of $26.16. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The firm had revenue of $71.55 million for the quarter, compared to the consensus estimate of $65.44 million. During the same quarter in the previous year, the business earned ($0.17) EPS. The firm’s quarterly revenue was up 21.5% on a year-over-year basis. Research analysts expect that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.

Insider Buying and Selling at Adaptive Biotechnologies

In related news, insider Sharon Benzeno sold 154,768 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $21.14, for a total transaction of $3,271,795.52. Following the transaction, the insider directly owned 221,278 shares of the company’s stock, valued at approximately $4,677,816.92. This trade represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Susan Bobulsky sold 11,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $18.00, for a total transaction of $198,000.00. Following the transaction, the insider owned 416,775 shares in the company, valued at approximately $7,501,950. The trade was a 2.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,306,971 shares of company stock valued at $27,894,120. 5.70% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on ADPT shares. Guggenheim raised their price target on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. Piper Sandler increased their price objective on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. TD Cowen raised their target price on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Finally, BTIG Research lifted their target price on shares of Adaptive Biotechnologies from $24.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Adaptive Biotechnologies currently has a consensus rating of “Moderate Buy” and an average price target of $24.42.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.